Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ASCL1
REST API REST API
Homo sapiens
ASCL1 is differentially expressed in 239 experiments: 155 organism parts: brain, thymus, ... (153 more);, 142 disease states: normal, lung adenocarcinoma, ... (140 more);, 68 cell types 329 cell lines 29 compound treatments and 76 other conditions.
Synonyms HASH1, ASH1, bHLHa46
Orthologs ascl1a (Danio rerio)   Q4JF73_CIOIN (Ciona intestinalis)   Ascl1 (Rattus norvegicus)   Ascl1 (Mus musculus)   Q4H3X5_CIOIN (Ciona intestinalis)   ASCL1 (Bos taurus)   ase (Drosophila melanogaster)   l(1)sc (Drosophila melanogaster)   ASCL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, pattern specification process, neuroblast proliferation, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, double-stranded DNA binding, regulation of cell proliferation, neurogenesis, transcription, DNA-dependent, negative regulation of apoptosis, positive regulation of Notch signaling pathway, glial cell differentiation, cell differentiation, sequence-specific DNA binding, neuroblast fate determination, positive regulation of transcription from RNA polymerase II promoter, nucleus, regulation of gene expression, regulation of Notch signaling pathway, neuron development, nervous system development, Notch signaling pathway, protein homodimerization activity, central nervous system neuron development, regulation of transcription from RNA polymerase II promoter, bHLH transcription factor binding, neuron migration, neuronal cell body, response to lithium ion, forebrain neuron differentiation, oligodendrocyte differentiation, positive regulation of neuron differentiation, adrenal chromaffin cell differentiation, positive regulation of neurogenesis, cerebral cortex development, spinal cord oligodendrocyte cell fate specification, noradrenergic neuron fate commitment, stomach neuroendocrine cell differentiation, E-box binding, lung neuroendocrine cell differentiation, subpallium neuron fate commitment, carotid body glomus cell differentiation, response to epidermal growth factor stimulus, response to retinoic acid, negative regulation of neuron differentiation, cellular response to magnetism, spinal cord oligodendrocyte cell differentiation, lung epithelial cell differentiation, oligodendrocyte cell fate commitment, olfactory pit development, sympathetic nervous system development, spinal cord association neuron differentiation, neuron fate commitment, positive regulation of neuron apoptosis, oligodendrocyte development, response to folic acid, regulation of timing of subpallium neuron differentiation, neuron fate specification, cerebral cortex GABAergic interneuron differentiation, sequence-specific DNA binding transcription factor activity, transcription factor binding transcription factor activity
InterPro Term HLH_DNA-bd
UniProt Accession P50553
Gene-Disease Assocation CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS
Search EB-eye ENSG00000139352
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-3526, E-MTAB-62, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
SW480
2
E-MEXP-1014, E-MTAB-37
NCIH524
1
E-MTAB-37
GM08930
1
E-TABM-321
NCIH1563
1
E-MTAB-37
323 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, E-GEOD-13987, ... (35 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-22373, E-GEOD-8286, E-GEOD-11755
testis - germ cell
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-3982, E-GEOD-12662
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
epidermal keratinocyte
1
E-GEOD-2822
bronchial epithelial
1
E-AFMX-5
62 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-GEOD-2466, E-MEXP-2069, ... (45 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
hepatocellular adenoma
2
E-MTAB-62, E-TABM-36
neuroblastoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
lung adenocarcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-2514
136 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-GEOD-5099, E-MEXP-941, E-GEOD-5339, ... (21 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-4600, E-GEOD-412, E-GEOD-5824, E-TABM-782, E-GEOD-7307, ... (8 experiments)
1mM GDC-0941
1
1
E-GEOD-20719
trans-hydroxytamoxifen
1
E-GEOD-4025
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
rapamycin
1
E-GEOD-5824
Cxcl12
1
1
E-GEOD-7307
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-TABM-36, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-MEXP-2069, E-MEXP-1648, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-2487, E-GEOD-4600

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-2508, E-GEOD-12293, E-GEOD-2466, E-GEOD-8052, E-GEOD-7307 ... (5 experiments)

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.297 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM